Apeiron Investment Group

Founded 2012
Founders Christian Angermayer


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 16
Average round size
The average size of a deal this fund participated in
Portfolio companies 12
Rounds per year 1.78
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Life Science
  • Health Care
  • Therapeutics
  • Biopharma

The leading representative office of defined VC is situated in the Sliema. The company was established in Europe in Malta.

The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The average startup value when the investment from Apeiron Investment Group is 10-50 millions dollars. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The fund is generally included in less than 2 deals every year.

We can highlight the next thriving fund investment areas, such as E-Commerce, Finance. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Springlane, Juvenescence, Zenhomes For fund there is no match between the country of its foundation and the country of its the most frequent investments - Germany.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Apeiron Investment Group, startups are often financed by Heliad Equity Partners, HV Holtzbrinck Ventures, TEV | Tengelmann Ventures. The meaningful sponsors for the fund in investment in the same round are Christian Angermayer, main incubator, Valar Ventures. In the next rounds fund is usually obtained by Longevity Vision Fund, IPGL, Grok Ventures.

The current fund was established by Christian Angermayer.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Apeiron Investment Group:
Typical Co-investors
Apeiron Investment Group is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Apeiron Investment Group:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Malta, NA - Malta
Funds with similar focus located in Malta, NA - Malta:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation


$4M06 Sep 2021

Olsam Group

Consumer Goods
$164M01 Sep 2021 United Kingdom, London

Health Care
$45M16 Mar 2021 Israel, Tel Aviv-Yafo

ATAI Life Sciences

Health Care
Life Science
$157M03 Mar 2021 Germany, Munich

Cambrian Biopharma

Life Science
$60M09 Feb 2021 United States, New York

Sensei Biotherapeutics

Health Diagnostics
Life Science
$30M11 Jan 2021 United States, " United States"}

Health Care
Medical Device
$5M15 Dec 2020 Germany, Berlin

ATAI Life Sciences

Health Care
Life Science
$93M24 Nov 2020 Germany, Munich

Sensei Biotherapeutics

Health Diagnostics
Life Science
$28M07 Oct 2020 United States, " United States"}
Olsam Group Raises $165M in Series A Equity and Debt Funding Round

– Olsam Group from London buys and scales e-commerce businesses.
– The company raised $165m in Series A equity and debt funding round.
– The equity funding was led by Christian Angermayer’s Apeiron Investment Group and Elevat3 Capital.
– Debt financing was led by North Wall Capital.

atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

– atai Life Sciences announced the closing of its $157m Series D financing round.
– The round was led by Apeiron Investment Group and joined by Woodline Partners LP.
– The proceeds from this financing will support the expansion and development of the Company’s diverse drug candidate pipeline and enabling technologies.
– In addition, the financing will provide the necessary runway to continue advancing its current clinical developments, as well as scale its experienced team in order to continue delivering key milestones.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Apeiron Investment Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: